The expression and clinical importance of Reg IV in different molecular subtypes of breast cancer
10.16571/j.cnki.1008-8199.2019.04.013
- VernacularTitle: 再生胰岛衍生家族成员4在不同分子分型乳腺癌中的表达及其与预后的关系
- Author:
Shan-shan SONG
1
;
Yan-hong NIE
1
;
Hong-xia WANG
1
;
Yong-fang WANG
1
;
Hao CHEN
1
Author Information
1. Department of Pathology, First People′s Hospital of Lianyungang, Affiliated Hospital of Xuzhou Medical University, Lianyungang 222061, Jiangsu, China
- Publication Type:Journal Article
- Keywords:
regenerating islet-derived family, member 4;
breast neoplasms;
molecular typing;
clinicopathological features
- From:
Journal of Medical Postgraduates
2019;32(4):401-405
- CountryChina
- Language:Chinese
-
Abstract:
Objective RegIV, which is the latest member of the regenerative gene family, has been found to be closely related to the development of various tumors, but rarely reported in invasive breast cancer. This article is intended to explore the expression levels of regenerative factor 4(regeneration islet-derived family, member 4, RegIV), and the correlation with clinicopathological features and prognosis in 4 molecular subtypes of breast cancer(LA, LB,HER-2+, TNBC). Methods Pathological data of 284 breast cancer patients from March 2011 to October 2017 in the department of pathology, Lianyungang first people’s hospital were collected. To analyze the expression of RegIV in different molecular subtypes (LA, LB, HER-2+, TNBC) and its relationship with clinicopathological features, we analyzed the expression level of RegIVmRNA in breast cancer and its prognosis of patients. Results The positive rates of Reg IV in Luminal A group, Luminal B group, HER-2 positive group and triple negative breast cancer were 52.11%（37/71）, 50.00%（42/84）, 65.22%（45/69）and 20.00%（12/60）,which was statistically significant when comparing them in pairs(P<0.01). The expression of RegIV was associated with tumor diameter, lymph node metastasis, TNM stage(P<0.01). The recurrence risk of breast cancer patients with high RegIV expression was lower than those with low RegIV expression (HR=0.59,95%CI:0.50-0.69). Further analysis found that the recurrence risk of LA breast cancer patients with high RegIV expression (HR=0.63,95%CI:0.48-0.82), and so it was with LB(HR=0.56,95%CI:0.40-0.76) and TNBC(HR=0.51,95%CI:0.36-0.71). Conclusion RegIV can provide reference for molecular subtypes diagnosis and it may be one of the indicators to evaluate the prognosis of breast cancer patients.
